Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.

Abstract

AIMS The demonstration that endothelin production is upregulated in pulmonary artery hypertension (PAH) served as the rationale for developing endothelin-receptor antagonists (ERAs) as a treatment for PAH. This article reviews the primary studies demonstrating efficacy of ERAs in PAH. MAIN METHODS Multicenter, placebo-controlled trials and open-label… (More)
DOI: 10.1016/j.lfs.2012.07.033

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics